Showing 1 - 10 of 15 Immune System Diseases

Status: Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This trial will study brentuximab vedotin to find out whether it is an effective treatment for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). Participants in this study will be older or will have other conditions that make them una ... Read more >

Status: Enrolling

Investigator: Sai ravi kiran Pingali

Study Coordinator: Juan Morales Viera

Phone: 786.803.2333

This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got worse) after stoppi ... Read more >

Status: Enrolling

Investigator: Sheetal Shroff

Study Coordinator:

Phone:

The purpose of the MycarinGstudy is to demonstrate the clinical efficacy and to assess safety and tolerability of rozanolixizumab in patients with generalized myasthenia gravis (MG). NCT number: NCT03971422 ... Read more >

Status: Open Not Enrolling

Investigator: Terry Clyburn

Study Coordinator: Rosbel Brito

Phone: 918.813.7873

This study is designed to observe the long term clinical outcomes of patient-specific knee arthroplasty in patients with osteoarthritis. ... Read more >

Status: Enrolling

Investigator: Jason Thonhoff

Study Coordinator:

Phone:

The purpose of this study is to measure the safety and effectiveness of Spinraza in adults with SMA. ... Read more >

Status: Enrolling

Investigator: Sheetal Shroff

Study Coordinator:

Phone:

The purpose of the MycarinGstudy is to evaluate the long-term safety, tolerability and long-term efficacy of rozanolixizumab in study participants with generalized myasthenia gravis (MG). NCT number: NCT04124965 ... Read more >

Status: Enrolling

Investigator: Sheetal Shroff

Study Coordinator:

Phone:

The primary objective of the study is: • To provide patients with CMS access to amifampridine phosphate therapy until the product becomes commercially available or development is discontinued. The secondary objective of the study is: • ... Read more >

Status: Enrolling

Investigator: Jasleen Randhawa

Study Coordinator: Pej Hemati

Phone: 713.441.3926

This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibod ... Read more >

Status: Open Not Enrolling

Investigator: Lisa Kopas

Study Coordinator:

Phone:

The purpose of this research is to study a medical device that is designed to produce lung volume reduction. This device is called the PulmonX Endobronchial Valve (EBV). It has not been approved by the Food and Drug Administration (FDA) and is c ... Read more >

Status: Open Not Enrolling

Investigator: Ericka Greene

Study Coordinator: Sharon Halton

Phone: 713.441.3420

The purpose of this protocol is to make available clinical findings, including blood pressure, pulmonary function tests, cardiac function tests, clinical evaluations, cognitive evaluations, performance tests, medications, routine blood work eval ... Read more >

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator:

Phone:

This is a registry of people with neuromuscular diseases. It is the intent to follow patients with ALS and other neuromuscular diseases to determine best practices for care delivery. ... Read more >

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Sharon Halton

Phone: 713.441.3420

This is a Phase III, prospective, multicenter study with two study parts (epochs) to evaluate the efficacy, safety, and tolerability of HYQVIA/HyQvia (IGI, 10% with recombinant human hyaluronidase (rHuPH20) administered subcutaneously) for maint ... Read more >

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator:

Phone:

The primary purpose of this study is to evaluate the safety and efficacy of ravulizumab for the treatment of participants with generalized myasthenia gravis (gMG). [NCT03920293] ... Read more >

Status: Enrolling

Investigator: Ahmed Gaber

Study Coordinator: Isioma Agboli

Phone: 713.447.368

Rabbit antithymocyte globulin (rATG) is approved for the treatment of acute rejection following kidney transplantation and is routinely administered as a series of 5-7 consecutive daily doses via central intravenous catheter. This prolonged cour ... Read more >

Status: Enrolling

Investigator: Maen Abdelrahim

Study Coordinator:

Phone:

RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and ... Read more >